Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivonescimab in Advanced/Metastatic Cutaneous Angiosarcoma
NCT07655570Phase 2Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Aug 2026
- Primary completion
- May 2027
- Countries
- 1
01
Overview
A Phase 2 trial of ivonescimab in cutaneous angiosarcoma (cAS), sponsored by University of Texas MD Anderson Cancer Center. Started Aug 2026; status: recruiting.
02
Drugs
ivonescimab
03
Conditions
cutaneous angiosarcoma (cAS)
Beyond the preview
Go deeper on NCT07655570.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07655570.